To evaluate mid-term oncological and functional outcomes in patients with prostate cancer treated by robot-assisted laparoscopic radical prostatectomy (RALP) at our institution. We retrospectively reviewed the medical records of 128 patients with prostate cancer who underwent RALP at our institution between February 2008 and April 2010.
To comprehensively evaluate the efficacy and safety of Retzius sparing (RS) for men undergoing robot-assisted laparoscopic prostatectomy (RARP). We searched four electronic databases and reference lists of relevant studies for eligible research published before March 11, 2019.
A highly practical and interesting study, CARD, was recently presented at ESMO and published in the NEJM. It’s a study that answers a lot of questions, creates a few others, and can be translated into the clinic relatively quickly. The CARD study randomized patients with castration-resistant prostate cancer (CRPC) to either treatment with cabazitaxel ( […]
At the European Society of Medical Oncology (ESMO) Congress 2019, the randomized phase 3 CARD trial was presented, with a simultaneous publication in the New England Journal of Medicine.1 This trial randomized 255 men with metastatic castration-resistant prostate cancer in a 1:1 fashion, who previously received docetaxel and an Androgen-Signaling-targeted Inhibitor (ASI), either abiraterone or […]
Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer Condition: Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer Intervention: Drug: Enzalutamide Other: Laboratory Biomarker Analysis Radiation: Radium Ra 223 Dichloride Purpose: This randomized phase II trial studies how well enzalutamide with […]
Alicia Morgans: Hi, I’m so excited to have here with me today, Dr. Lynn Seely, who is the President and CEO of Myovant Sciences. You gave such an engaging lecture today in the women’s symposium, which was an offshoot of the Prostate Cancer Foundation’s annual meeting. And I would love to hear you just summarize […]
Charles Ryan: Hello from PCF 2019. I’m delighted to be joined by Dr. June Chan, who is Professor of Epidemiology and Biostatistics and Urology, where she is the Stephen and Christine Bird Safeway distinguished professor at the University of California, San Francisco. She also holds the title of Vice Chair for Education in the Department […]
Charles Ryan: Hello from PCF 2019. I’m delighted to be joined by Dr. June Chan, who is Professor of Epidemiology and Biostatistics and Urology, where she is the Stephen and Christine Burd-Safeway Distinguished Professor at the University of California, San Francisco. She also holds the title of Vice Chair for Education in the Department of […]
Alicia Morgans: Hi. I am delighted to have here with me today Dr. Matthew Smith, who is a Professor of Medicine at Harvard Medical School and a GU Medical Oncologist at Massachusetts General Hospital in Boston. Thank you so much for talking with me today. Matthew Smith: Happy to be here. Alicia Morgans: Great. One […]
Charles Ryan: Hello from PCF 2019 in La Costa, Carlsbad, California. I’m delighted to be joined by Ken Pienta, who is the Donald S. Coffey Professor of Urology. He’s a Professor of Oncology, and a Professor of Pharmacology and Molecular Sciences at Johns Hopkins in Baltimore. Ken, always a pleasure to talk to you. Kenneth […]
